Retatrutide vs Semaglutide vs Tirzepatide: Triple vs Dual vs Single Agonists

**Disclaimer:** This article is provided for educational and research purposes only. These are prescription medications approved for specific indications. Nothing in this article constitutes medical advice or a recommendation for use outside approved labeling. [Semaglutide](/research/semaglutide-metabolic) and [tirzepatide](/research/tirzepatide-dual-agonist) are FDA-approved for certain metabolic indications; [retatrutide](/catalog/retatrutide-10) remains investigational.

Introduction

The incretin-based metabolic therapy landscape has evolved rapidly from single-receptor agonism (semaglutide, targeting GLP-1R) to dual agonism (tirzepatide, targeting GLP-1R and GIPR) to triple agonism (retatrutide, targeting GLP-1R, GIPR, and GCGR). Each additional receptor target expands the metabolic signaling network engaged, with potentially greater efficacy but also increased mechanistic complexity. Understanding the receptor pharmacology and clinical evidence for each agent is essential for researchers studying incretin biology and metabolic regulation.

Receptor Pharmacology

Semaglutide: GLP-1 Receptor Agonist

Semaglutide is a selective GLP-1 receptor agonist with 94% sequence homology to native GLP-1. Its key structural modifications --- an amino acid substitution at position 8 (Aib) and a C-18 fatty diacid side chain linked via a spacer at Lys26 --- confer albumin binding that extends its half-life to approximately 7 days, enabling once-weekly dosing. Semaglutide activates GLP-1 receptors on pancreatic beta cells (potentiating glucose-dependent insulin secretion), on hypothalamic neurons (reducing appetite and food intake), and on gastric smooth muscle (slowing gastric emptying).

Knudsen and Lau (2019) reviewed semaglutide's pharmacology, noting that its high potency at GLP-1R is achieved through both increased receptor binding affinity and prolonged receptor engagement compared to earlier GLP-1RAs like liraglutide.

Tirzepatide: Dual GLP-1/GIP Receptor Agonist

Tirzepatide is a 39-amino-acid peptide that acts as an agonist at both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Based on the native GIP sequence with modifications enabling GLP-1R cross-reactivity, tirzepatide has approximately 5-fold higher affinity for GIPR than GLP-1R. A C-20 fatty diacid side chain provides albumin binding and a half-life of approximately 5 days.

The inclusion of GIP receptor agonism adds metabolic signaling that complements GLP-1R activation. GIP acts on adipocytes to promote lipid storage and insulin sensitivity, on osteoblasts to maintain bone density, and on pancreatic beta cells to enhance insulin secretion. Willard et al. (2020) characterized tirzepatide's receptor pharmacology, demonstrating that the dual agonism produces distinct intracellular signaling profiles compared to selective GLP-1R agonism --- biased toward cAMP production with reduced beta-arrestin recruitment, which may reduce receptor desensitization and maintain efficacy over time.

Retatrutide: Triple GLP-1/GIP/Glucagon Receptor Agonist

Retatrutide (LY3437943) is a single molecule that agonizes three receptors: GLP-1R, GIPR, and the glucagon receptor (GCGR). The addition of glucagon receptor agonism introduces a fundamentally different metabolic lever. Glucagon increases hepatic glucose production (gluconeogenesis and glycogenolysis), stimulates lipolysis in adipose tissue, and increases energy expenditure through activation of hepatic fatty acid oxidation and thermogenesis in brown adipose tissue.

Coskun et al. (2022) described retatrutide's pharmacology, demonstrating that in preclinical models, the triple agonist produced greater weight loss than either GLP-1R agonism or dual GLP-1R/GIPR agonism alone. The glucagon component drives energy expenditure increases that the other two receptors do not provide --- essentially increasing calories burned rather than only reducing calories consumed.

Clinical Trial Weight Loss Data

Semaglutide: STEP Program

The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program established semaglutide 2.4 mg weekly as a benchmark in obesity pharmacotherapy. In STEP 1, Wilding et al. (2021) reported that semaglutide 2.4 mg weekly produced a mean body weight reduction of -14.9% from baseline at 68 weeks in adults with overweight or obesity (n=1,961), compared to -2.4% with placebo. Approximately 32% of participants achieved weight loss of 20% or greater.

Tirzepatide: SURMOUNT Program

Tirzepatide was evaluated in the SURMOUNT trial program. Jastreboff et al. (2022) published the SURMOUNT-1 results, a 72-week trial in 2,539 adults with obesity. At the highest dose (15 mg weekly), tirzepatide produced a mean weight reduction of -20.9% from baseline, with 36% of participants achieving weight loss of 25% or greater. The 10 mg and 5 mg doses produced -19.5% and -15.0% weight reductions, respectively. These results exceeded the semaglutide benchmark, consistent with the hypothesis that dual agonism produces greater metabolic benefit than single GLP-1R agonism.

Retatrutide: Phase 2 Results

Jastreboff et al. (2023) published the phase 2 trial of retatrutide in the New England Journal of Medicine. In 338 adults with obesity, the highest dose group (12 mg weekly) achieved a mean weight reduction of -24.2% at 48 weeks, with some participants losing over 30% of body weight. This 48-week result exceeded the 68-week and 72-week benchmarks of semaglutide and tirzepatide respectively, suggesting that triple agonism may represent a further step-change in weight loss efficacy. Importantly, weight loss trajectories had not plateaued at 48 weeks, suggesting that longer treatment durations could yield even greater reductions.

Side Effect Profiles

All three agents share gastrointestinal side effects related to GLP-1R agonism: nausea, vomiting, diarrhea, and constipation. These events are generally most frequent during dose titration and decrease over time.

Semaglutide's gastrointestinal AE profile in STEP 1 included nausea (44% vs 18% placebo), diarrhea (30% vs 16%), vomiting (24% vs 6%), and constipation (24% vs 11%). Discontinuation due to AEs was 7% in the semaglutide group.

Tirzepatide showed similar GI side effects in SURMOUNT-1, with nausea occurring in 24--33% across dose groups (vs 10% placebo). Discontinuation rates due to AEs were 4.3--7.1% across tirzepatide dose groups, somewhat lower than semaglutide.

Retatrutide's glucagon receptor agonism introduces additional considerations. Glucagon increases hepatic glucose output, which could theoretically counteract the glucose-lowering effects of GLP-1R and GIPR agonism. In the phase 2 trial, no significant increases in fasting glucose or HbA1c were observed in non-diabetic participants, suggesting that the GLP-1R and GIPR components adequately counterbalance the glucagon effect on glycemia. However, increases in heart rate (2--4 bpm) were noted at higher doses, likely related to the combined sympathomimetic effects of GLP-1R and GCGR activation. Gastrointestinal AEs were similar to the other agents, with nausea and diarrhea being most common.

Mechanistic Complementarity

The progression from single to triple agonism reflects an expanding understanding of metabolic regulation. GLP-1R agonism reduces appetite and slows gastric emptying (the "eat less" mechanism). GIPR agonism enhances insulin sensitivity, improves lipid handling in adipocytes, and may amplify central appetite suppression (the "metabolize better" mechanism). GCGR agonism increases hepatic lipid oxidation, stimulates thermogenesis, and raises energy expenditure (the "burn more" mechanism).

This mechanistic complementarity explains the stepwise increase in weight loss efficacy: semaglutide (GLP-1R only) achieves ~15%, tirzepatide (GLP-1R + GIPR) achieves ~21%, and retatrutide (GLP-1R + GIPR + GCGR) achieves ~24% weight loss at the highest studied doses. Each additional receptor target addresses a different component of the energy balance equation.

Summary

The evolution from semaglutide to tirzepatide to retatrutide represents a systematic expansion of incretin receptor targeting, with each additional agonist mechanism addressing a complementary aspect of metabolic regulation. Semaglutide's selective GLP-1R agonism established the foundation with robust appetite suppression and glycemic control. Tirzepatide's addition of GIPR agonism improved insulin sensitivity and lipid handling. Retatrutide's further addition of GCGR agonism introduces energy expenditure increases through hepatic lipid oxidation and thermogenesis. Phase 2 data for retatrutide suggest the largest weight reductions observed with any pharmacological agent, though phase 3 confirmation and long-term safety data are awaited.

*This article is provided for informational and research purposes only. Viking Labs does not sell products intended for human consumption, and nothing in this article should be construed as medical advice.*